
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc is currently advancing several promising biopharmaceutical products, highlighted by an increased valuation of STRO-004 to $50 million based on strong preclinical data and upcoming IND filing. The company has demonstrated significant improvements in overall survival and progression-free survival metrics for its Tivdak product, suggesting its competitive therapeutic potential in metastatic cervical cancer. Additionally, the pipeline encompasses various candidates targeting multiple cancers, reflecting a diverse approach to addressing significant unmet medical needs in oncology and autoimmune disorders.
Bears say
Sutro Biopharma faces significant challenges due to the limitations of its antibody candidates, particularly their preferential binding to specific conformations, which hinders uniform tumor targeting and affects the overall performance of antibody-drug conjugates (ADCs). The complexities surrounding suboptimal binding impact crucial factors such as internalization, payload delivery, and efficacy, potentially undermining the therapeutic effectiveness of its pipeline products. Additionally, adverse effects observed with similar targeting strategies, such as off-tissue toxicity associated with Tivdak, raise concerns about the safety and acceptability of Sutro's therapies in clinical applications.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares